IP Verse

Mesenchymal Stem Cells And Uses Therefor - EP2824175

The patent EP2824175 was granted to Mesoblast on Oct 28, 2020. The application was originally filed on Mar 15, 2005 under application number EP14172807A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2824175

MESOBLAST
Application Number
EP14172807A
Filing Date
Mar 15, 2005
Status
Patent Maintained As Amended
Sep 25, 2020
Grant Date
Oct 28, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

FRIEDRICHAug 29, 2018BREUER FRIEDRICH HAHNER PATENTANWALTE PARTG MBBADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS5486359
DESCRIPTIONUS6355239
OPPOSITIONWO0160348
SEARCHUS2003139410
SEARCHWO0180865
SEARCHWO9951247
SEARCHWO9951275

Non-Patent Literature (NPL) Citations (90) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BALLAS ET AL., J. CELL. BIOCHEM. SUPPL., (2002), vol. 38, page 20-
DESCRIPTION- BARTHOLOMEW ET AL., EXP. HEMATOL, (2002), vol. 30, page 42-
DESCRIPTION- CHOPP ET AL., NEUROREPORT, (2000), vol. 11, page 3001-
DESCRIPTION- DEKOK ET AL., CLIN. ORAL IMPLANTS RES., (2003), vol. 14, page 481-
DESCRIPTION- DENICOLA ET AL., BLOOD, (2002), vol. 99, page 3838-
DESCRIPTION- DEVINE ET AL., CANCER J., (2001), vol. 7, page 576-
DESCRIPTION- DINICOLA ET AL., BLOOD, (2002), vol. 99, page 3838-
DESCRIPTION- DZIONEK ET AL., J. IMMUNOL., (2000), vol. 165, page 6037-
DESCRIPTION- EAVES ET AL., ANN. N.Y. ACAD. SCI., (2001), vol. 938, page 63-
DESCRIPTION- FAKUDA, ARTIF. ORGANS, (2001), vol. 25, page 187-
DESCRIPTION- HARRIS ET AL., TRENDS IMMUNOL., (2002), vol. 23, page 144-
DESCRIPTION- HAYNESWORTH ET AL., BONE, (1992), vol. 13, page 69-
DESCRIPTION- HAYNESWORTH ET AL., J. CELL. PHYSIOL., (1996), vol. 166, page 585-
DESCRIPTION- HOROWITZ ET AL., PROC. NAT. ACAD. SCI., (2002), vol. 99, page 8932-
DESCRIPTION- HORWITZ ET AL., BLOOD, (2001), vol. 97, page 1227-
DESCRIPTION- KINGSLEY ET AL., J. IMMUNOL., (2002), vol. 168, page 1080-
DESCRIPTION- KOC ET AL., J. CLIN. ONCOL., (2000), vol. 18, page 307-
DESCRIPTION- LE BLANC ET AL., EXP. HEMATOL., (2003), vol. 31, page 890-
DESCRIPTION- LEBLANC ET AL., EXP. HEMATOL., (2003), vol. 31, page 890-
DESCRIPTION- LEBLANC ET AL., EXP. HERNATOL., (2003), vol. 31, page 890-
DESCRIPTION- LEBLANC ET AL., SCAND J. IMMUNOL, (2003), vol. 57, page 11-
DESCRIPTION- LEBLANC ET AL., SCAND. J. LMMUNOL., (2003), vol. 57, page 11-
DESCRIPTION- MACKENZIE ET AL., BLOOD CELLS MOL. DIS., (2002), vol. 27-
DESCRIPTION- MAJUMDAR ET AL., HEMATOTHER. STEM CELL RES., (2000), vol. 9, page 841-
DESCRIPTION- MAJUMDAR ET AL., J. BIOMED. SCI., (2003), vol. 10, page 228-
DESCRIPTION- NOEL, CURR. OPIN. INVESTIG, DRUGS, (2002), vol. 3, page 1000-
DESCRIPTION- PEREIRA ET AL., PROC. NAT. ACAD. SCI., (1998), vol. 95, page 1142-
DESCRIPTION- PITTENGER ET AL., SCIENCE, (1999), vol. 284, page 143-
DESCRIPTION- POTIAN ET AL., J. IMMUNOL., (2003), vol. 171, page 3426-
DESCRIPTION- PROCKOP, SCIENCE, (1997), vol. 276, page 71-
DESCRIPTION- SANCHEZ-RAMOS ET AL., EXP. NEUROL., (2001), vol. 171, page 109-
DESCRIPTION- SCHWARTZ ET AL., HUM. GENE THER., (1999), vol. 10, page 2539-
DESCRIPTION- SHAKE ET AL., ANN. THORAC. SURA., (2002), vol. 73, page 1919-
DESCRIPTION- TOMA ET AL., CIRCULATION, (2002), vol. 105, page 93-
DESCRIPTION- TOMITA ET AL., CIRCULATION, (1999), vol. 100, page 247-
DESCRIPTION- TSE ET AL., TRANSPLANTATION, (2003), vol. 75, page 389-
DESCRIPTION- TSE, TRANSPLANTATION, (2003), vol. 75, page 389-
DESCRIPTION- VASSLLLOU ET AL., CELL. IMMUNOL., (2003), vol. 223, page 120-
DESCRIPTION- WAGERS ET AL., GENE THERAPY, (2002), vol. 9, page 606-
DESCRIPTION- WAKITANI ET AL., MUSCLE NERVE, (1995), vol. 18, page 1417-
DESCRIPTION- WOODBURY ET AL., J. NEUROSCL. RES., (2002), vol. 69, page 908-
DESCRIPTION- WU ET AL., J. NEUROSCI. RES., (2003), vol. 72, page 393-
DESCRIPTION- WU ET AL., TRANSPLANTATION, (2003), vol. 75, page 679-
OPPOSITION- BACIGALUPO, A. et al., "Management of acute graft versus host disease (GvHD)", Hematol. J., (200405), vol. 5, no. 3, pages 189 - 196-
OPPOSITION- BAECKER-ALLAN, C. et al., "CD4+ CD25 high regulatory cells in human peripheral blood", J. Immunol., (20010000), vol. 167, pages 1245 - 1253, XP055518791-
OPPOSITION- BAECKER-ALLAN, C. et al., "CD4+ CD25 high regulatory cells in human peripheral blood", J. Immunol., (2001), vol. 167, pages 1245 - 1253-
OPPOSITION- BARRY, F. P., "Biology and clinical applications of mesenchymal stem cells", Birth defects Res., (2003), vol. 69, pages 250 - 256-
OPPOSITION- BARRY F.P.; MURPHY J.M., "Mesenchymal stem cells: Clinical applications and biological characterization.", INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, GB, (20040401), vol. 36, no. 4, doi:10.1016/j.biocel.2003.11.001, ISSN 1357-2725, pages 568 - 584-
OPPOSITION- BARTHOLOMEW, A. et al., "MESENCHYMAL STEM CELLS SUPPRESS LYMPHOCYTE PROLIFERATION IN VITRO AND PROLONG SKIN GRAFT SURVIVAL IN VIVO", Exp. Hematol., (2002), vol. 30, no. 1, pages 42 - 48-
OPPOSITION- DEANS, R. J. et al., "Mesenchymal stem cells: Biology and potential clinical uses", Exp. Hematol., (2000), vol. 28, no. 8, pages 875 - 884-
OPPOSITION- DI NICOLA, M. et al., "Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli", Blood, (20020515), vol. 99, no. 10, pages 3838 - 3843-
OPPOSITION- DJOUAD, F. et al., "IMMUNOSUPPRESSIVE EFFECT OF MESENCHYMAL STEM CELLS FAVORS TUMOR GROWTH IN ALLOGENEIC ANIMALS", Blood, (2003), vol. 102, no. 10, pages 3837 - 3844-
OPPOSITION- Gisella Borzone et al, "Bleomycin-Induced Chronic Lung Damage Does Not Resemble Human Idiopathic Pulmonary Fibrosis", American Journal of Respiratory and Critical Care Medicine, (20010601), vol. 163, no. 7, doi:10.1164/ajrccm.163.7.2006132, ISSN 1073449X, pages 1648 - 1653-
OPPOSITION- GONZALEZ MANUEL A, ET AL, "Adipose-Derived Mesenchymal Stem Cells Alleviate Experimental Colitis by Inhibiting Inflammatory and Autoimmune Responses", Gastroenterology, US, (20090301), vol. 136, no. 3, ISSN 0016-5085, pages 978 - 989-
OPPOSITION- GRAY, J. D. et al., "Generation of an inhibitory circuit involving CD8+ T cells, IL-2, and NK cell-derived TGF-beta: contrasting effects of anti-CD2 and anti-CD3", J. Immunol., (19980000), vol. 160, no. 5, pages 2248 - 2254, XP002099413-
OPPOSITION- GRAY, J. D. et al., "Generation of an inhibitory circuit involving CD8+ T cells, IL-2, and NK cell-derived TGF-beta: contrasting effects of anti-CD2 and anti-CD3", J. Immunol., (1998), vol. 160, no. 5, pages 2248 - 2254-
OPPOSITION- GRAY, J. D. et al., "THE ROLE OF TRANSFORMING GROWTH FACTOR BETA IN THE GENERATION OF SUPPRESSION: AN INTERACTION BETWEEN CD8+ T AND NK CELLS", J. Exp. Med., (1994), vol. 180, no. 5, pages 1937 - 1942-
OPPOSITION- JIANG, H. et al., "an integrated view of suppressor t cell subsets in immunoregulation", J. Clin. Invest., (20041100), vol. 114, no. 9, pages 1198 - 1208, XP055518799-
OPPOSITION- JIANG, H. et al., "an integrated view of suppressor t cell subsets in immunoregulation", J. Clin. Invest., (200411), vol. 114, no. 9, pages 1198 - 1208-
OPPOSITION- JORGENSEN, C. et al., "Mesenchymal stem cells and rheumatoid arthritis", Joint Bone Spine, (20030000), vol. 70, pages 483 - 485, XP009145230-
OPPOSITION- JORGENSEN, C. et al., "Mesenchymal stem cells and rheumatoid arthritis", Joint Bone Spine, (2003), vol. 70, pages 483 - 485-
OPPOSITION- Katie Kingwell, "InterMune and Boehringer blaze trails for idiopathic pulmonary fibrosis drugs", Nat. Rev./ Drug Discovery, (20140701), vol. 13, doi:10.1038/nrd4382, pages 483 - 484-
OPPOSITION- KRAMPERA, M. et al., "- Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide", Blood, (2003), vol. 101, no. 9, pages 3722 - 3729-
OPPOSITION- LEVINGS, M. K. et al., "Human CD2s+cn4+ T Suppressor Cell Clones Produce Transforming Growth Factor beta but not Interleukin 10, and Are Distinct from Type 1 T Regulatory Cells", J. Exp. Med., (20021118), vol. 196, no. 10, pages 1335 - 1346-
OPPOSITION- LEVINGS, M. K. et al., "Human CD2s+cn4+ T Suppressor Cell Clones Produce Transforming Growth Factor beta but not Interleukin 10, and Are Distinct from Type 1 T Regulatory Cells", J. Exp. Med., (20021118), vol. 196, no. 10, pages 1335 - 1346, XP055518788-
OPPOSITION- MAJUMDAR, M. K. et al., "Characterization and functionality of cell surface molecules on human mesenchymal stem cells", J. Biomed. Sci., (2003), vol. 10, no. 2, pages 22 8 - 241-
OPPOSITION- Moore B.B.; Hogaboam C.M., "Murine models of pulmonary fibrosis", American Journal of PhysiologyLung Cellular and Molecular Physiology, (20080101), vol. 294, no. 2, pages L152 - L160-
OPPOSITION- ORTIZ, L. A. et al., "Mesenchymal stem cell engraftment in lung is enhanced bleomycin exposure and ameliorates its fibrotic effects", Proceedings Natl. Acad. Sci. USA, (2003), vol. 100, no. 14, pages 8407 - 8411-
OPPOSITION- RAKEBRANDT, N. et al., "regulatory T cells:balancing protection versus pathology", Swiss Med. Wkly., (20160806), vol. 146, pages 1 - 8-
OPPOSITION- RAKEBRANDT, N. et al., "regulatory T cells:balancing protection versus pathology", Swiss Med. Wkly., (20160806), vol. 146, pages 1 - 8, XP055518807-
OPPOSITION- RASMUSSON, I. et al., "Human mesenchymal stem cells increase interleukin-2 and soluble IL -2 receptor in mixed lymphocyte cultures", Bone Marrow Transplant, (20040000), vol. 33, page s87, XP055496529-
OPPOSITION- RASMUSSON, I. et al., "Human mesenchymal stem cells increase interleukin-2 and soluble IL -2 receptor in mixed lymphocyte cultures", Bone Marrow Transplant, (2004), vol. 33, page s87-
OPPOSITION- Rasmusson, I., "Immune modulation by mesenchymal stem cells", Experimental Cell Research, AMSTERDAM, NL, (20060715), vol. 312, no. 12, doi:10.1016/j.yexcr.2006.03.019, ISSN 0014-4827, pages 2169 - 2179-
OPPOSITION- SHEVACH, E. M. et al., "Regulatory/ suppressor T cells in health and disease", Arthritis & Rheumatism, (20040000), vol. 50, no. 9, pages 2721 - 2724, XP055518797-
OPPOSITION- SHEVACH, E. M. et al., "Regulatory/ suppressor T cells in health and disease", Arthritis & Rheumatism, (2004), vol. 50, no. 9, pages 2721 - 2724-
OPPOSITION- YAMAGIWA, S. et al., "A role for TGF-beta in the generation and expansion of CD4+CD25+ regulator y T cells from human peripheral blood", J. Immunol., (20010000), vol. 166, no. 12, pages 7282 - 7289, XP002969113-
OPPOSITION- YAMAGIWA, S. et al., "A role for TGF-beta in the generation and expansion of CD4+CD25+ regulator y T cells from human peripheral blood", J. Immunol., (2001), vol. 166, no. 12, pages 7282 - 7289-
OPPOSITION- ZAPPIA EMANUELA, ET AL, "Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy", BLOOD, US, (20050901), vol. 106, no. 5, ISSN 0006-4971, pages 1755 - 1761-
OPPOSITION- BARRY, F. P., "Biology and clinical applications of mesenchymal stem cells", Birth defects Res., (20030000), vol. 69, pages 250 - 256, XP002976497
OPPOSITION- MAJUMDAR, M. K. et al., "Characterization and functionality of cell surface molecules on human mesenchymal stem cells", J. Biomed. Sci., (20030000), vol. 10, no. 2, pages 22 8 - 241, XP009164891
OPPOSITION- DEANS, R. J. et al., "Mesenchymal stem cells: Biology and potential clinical uses", Exp. Hematol., (20000000), vol. 28, no. 8, pages 875 - 884, XP002201188
OPPOSITION- BARTHOLOMEW, A. et al., "MESENCHYMAL STEM CELLS SUPPRESS LYMPHOCYTE PROLIFERATION IN VITRO AND PROLONG SKIN GRAFT SURVIVAL IN VIVO", Exp. Hematol., (20020000), vol. 30, no. 1, pages 42 - 48, XP008075907
OPPOSITION- BACIGALUPO, A. et al., "Management of acute graft versus host disease (GvHD)", Hematol. J., (20040500), vol. 5, no. 3, pages 189 - 196, XP055496392
OPPOSITION- ORTIZ, L. A. et al., "Mesenchymal stem cell engraftment in lung is enhanced bleomycin exposure and ameliorates its fibrotic effects", Proceedings Natl. Acad. Sci. USA, (20030000), vol. 100, no. 14, pages 8407 - 8411, XP003015827
OPPOSITION- LE BLANC, K., "Immunomodulatory effects of fetal and adult mesenchymal stem cells", Cytotherapy, (20030000), vol. 5, no. 6, pages 485 - 489, XP008075543
OPPOSITION- GRAY, J. D. et al., "THE ROLE OF TRANSFORMING GROWTH FACTOR BETA IN THE GENERATION OF SUPPRESSION: AN INTERACTION BETWEEN CD8+ T AND NK CELLS", J. Exp. Med., (19940000), vol. 180, no. 5, pages 1937 - 1942, XP000961145
OPPOSITION- KRAMPERA, M. et al., "- Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide", Blood, (20030000), vol. 101, no. 9, pages 3722 - 3729, XP055496530
OPPOSITION- DJOUAD, F. et al., "IMMUNOSUPPRESSIVE EFFECT OF MESENCHYMAL STEM CELLS FAVORS TUMOR GROWTH IN ALLOGENEIC ANIMALS", Blood, (20030000), vol. 102, no. 10, pages 3837 - 3844, XP002468564
OPPOSITION- DI NICOLA, M. et al., "Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli", Blood, (20020515), vol. 99, no. 10, pages 3838 - 3843, XP002982803
SEARCH- LE BLANC K, "IMMUNOMODULATORY EFFECTS OF FETAL AND ADULT MESENCHYMAL STEM CELLS", CYTOTHERAPY, ISIS MEDICAL MEDIA, OXFORD, GB, (20030101), vol. 5, no. 6, doi:10.1080/14653240310003611, ISSN 1465-3249, pages 485 - 489, XP008075543 [X] 1 * whole document esp. page 488 * [Y] 1-6,9,10,15

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents